genOway, a leading company in the development of genetically modified research models, has announced an important milestone in expanding its strategic alliance with Merck, a leading science company and technology and genome editing.

In December 2018, genOway acquired the exclusive rights of the founding portfolio of Merck's CRISPR / Cas9 in the rodent field (all applications involving rodent or animal cells). Today, the two companies have further strengthened their collaboration by signing an additional license that grants genOway non-exclusive rights to commercialize the development and use of all other animal cell models for their clients' internal research, as well as to Commercial exploitation.

Both Merck and genOway have identified research fields where they can combine their respective technologies and experience in order to develop and validate new products and solutions related to CRISPR / Cas9. Merck's patented CRISPR integration technology is a solid starting point through which innovation can be developed and promoted.